FDA's veterinary center agrees to Loyal's study design for a dog lifespan trial, a first for a longevity study

Loyal

The FDA's Center for Veterinary Medicine granted protocol concurrence for Loyal's companion dog longevity study, confirming the agency agreed that the study design could demonstrate whether a drug extends both lifespan and healthspan. This represents the first time the FDA has accepted a clinical study designed to show a drug extends lifespan rather than treating a single disease.

• FDA approved study design for demonstrating lifespan and healthspan extension in companion dogs.
• First FDA concurrence for a clinical study claiming lifespan extension rather than disease-specific benefit.
• If results are positive, findings would support bringing the drug to market for dogs nationwide.
• FDA approval is not a guarantee of eventual drug authorization; clinical trial results must still demonstrate safety and efficacy.